CA64082X2032
© Newsfile
23.10.2023
NGEN
LISTED
TSX
NervGen Pharma Receives Fast Track Designation for NVG-291 for the Treatment of Individuals with Spinal Cord Injury
News Preview
Designation Facilitates and Expedites Development of Drugs for Patients with Serious Unmet Medical Needs Enrollment Progressing in NVG-291 Phase 1b/2a Clinical Trial, with Initial Cohort Data Expected in Mid-2024Vancouver, British Columbia--(Newsfile Corp. - October 23, 2023) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQX: NGENF), a clinical stag...
Themefolio
Profiler
Peergroup
© Newsfile
17.10.2023
NGEN
LISTED
TSX
NervGen Pharma Appoints John Ruffolo to Board of Directors
News Preview
Extensive experience in private equity, venture capital and advising high growth, innovative companiesBrings personal experience and knowledge of spinal cord injury to NervGen's board Important board addition joins as Company advances clinical milestone with Phase 1b/2a study of NVG-291 underway.Vancouver, British Columbia--(Newsfile Corp. - Octobe...
Themefolio
Profiler
Peergroup
© Newsfile
25.09.2023
NGEN
LISTED
TSX
NervGen Pharma Announces First Subject Dosed in Landmark Phase 1b/2a Clinical Trial for NVG-291 in Spinal Cord Injury
News Preview
Chronic spinal cord injury cohort results expected in mid-2024 Subacute spinal cord injury cohort results expected in late 2024/early 2025Vancouver, British Columbia--(Newsfile Corp. - September 25, 2023) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQX: NGENF), a clinical stage biotech company dedicated to developing innovative solutions for the treatme...
Themefolio
Profiler
Peergroup
Worth to know
20.10.2025
Short Selling Radar
USA, Europe, Asia
Track Short Selling Activities worldwide
Knowing what matters
Short sale statistics, hedge fund activities and much more user-friendly information
© Newsfile
11.09.2023
NGEN
LISTED
TSX
NervGen Pharma to Present at 2023 International Spinal Research Trust Network Meeting
News Preview
Vancouver, British Columbia--(Newsfile Corp. - September 11, 2023) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQX: NGENF) ("NervGen" or the "Company"), a clinical stage biotech company dedicated to developing innovative solutions for the treatment of nervous system damage, announced today that its Chief Medical Officer, Dr. Daniel Mikol, will pres...
Themefolio
Profiler
Peergroup
Swarmalpha i/o · The Event Futures Prediction X
20.10.2025
© Newsfile
05.09.2023
NGEN
LISTED
TSX
NervGen Pharma to Present on Its Drug Candidate NVG-291 and Spinal Cord Injury at the H.C. Wainwright 25th Annual Global Investment Conference
News Preview
Vancouver, British Columbia--(Newsfile Corp. - September 5, 2023) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQX: NGENF), a clinical stage biotech company dedicated to developing innovative solutions for the treatment of nervous system damage, announced today that President & CEO, Mike Kelly, will present at the H.C. Wainwright 25th Annual Global I...
Themefolio
Profiler
Peergroup
© Newsfile
22.08.2023
NGEN
LISTED
TSX
NervGen Pharma to Present on its Drug Candidate NVG-291 and Spinal Cord Injury at Investor Conference
News Preview
Vancouver, British Columbia--(Newsfile Corp. - August 22, 2023) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQX: NGENF), a clinical stage biotech company dedicated to developing innovative solutions for the treatment of nervous system damage, announced today that members of its management team will present at the KOL Discussion on Spinal Cord Injury hos...
Themefolio
Profiler
Peergroup
© Newsfile
09.08.2023
NGEN
LISTED
TSX
NervGen Pharma Reports Q2 2023 Financial Results and Operational Updates
News Preview
Landmark Phase 1a/2b clinical trial of NVG-291 proceeds with recruitment of individuals with spinal cord injury; results expected in mid-2024 Seasoned life sciences executive, Mike Kelly, appointed President & CEOAwarded grant of up to US$3.18 million from Wings for Life to support clinical trialVancouver, British Columbia--(Newsfile Corp. - Au...
Themefolio
Profiler
Peergroup
© Newsfile
08.08.2023
NGEN
LISTED
TSX
NervGen Pharma to Proceed with Landmark Phase 1b/2a Clinical Trial for NVG-291 in Spinal Cord Injury Having Completed FDA Review and Received IRB Approval
News Preview
Recruitment of individuals with spinal cord injury (SCI) initiated at Shirley Ryan AbilityLab in ChicagoChronic SCI cohort results expected in mid-2024 and subacute SCI cohort results in late 2024/early 2025Vancouver, British Columbia--(Newsfile Corp. - August 8, 2023) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQX: NGENF), a clinical stage biotech com...
Themefolio
Profiler
Peergroup
© Newsfile
27.06.2023
NGEN
LISTED
TSX
NervGen Pharma to Receive More than US$3 Million from Wings for Life to Support Upcoming Clinical Study in Spinal Cord Injury
News Preview
Vancouver, British Columbia--(Newsfile Corp. - June 27, 2023) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQX: NGENF) ("NervGen" or the "Company"), a clinical stage biotech company dedicated to developing innovative solutions for the treatment of nervous system damage, announced today that it has been awarded a grant of up to US$3.18 million from Wings...
Themefolio
Profiler
Peergroup
© Newsfile
20.06.2023
NGEN
LISTED
TSX
NervGen Pharma to Present at Upcoming Investor Conferences
News Preview
Vancouver, British Columbia--(Newsfile Corp. - June 20, 2023) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQX: NGENF) ("NervGen" or the "Company"), a clinical stage biotech company dedicated to developing innovative solutions for the treatment of nervous system damage, announced today that members of its management will be presenting at two upcoming inv...
Themefolio
Profiler
Peergroup
© Newsfile
03.06.2023
NGEN
LISTED
TSX
NervGen Pharma Extends the Expiry Date of Certain Stock Options
News Preview
Vancouver, British Columbia--(Newsfile Corp. - June 2, 2023) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQX: NGENF) ("NervGen" or the "Company"), a clinical stage biotech company dedicated to developing innovative solutions for the treatment of nervous system damage, announced a two-year extension of the expiry date of certain stock options (the "Optio...
Themefolio
Profiler
Peergroup
© Newsfile
23.05.2023
NGEN
LISTED
TSX
NervGen Pharma Grants Stock Options
News Preview
Vancouver, British Columbia--(Newsfile Corp. - May 23, 2023) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQX: NGENF) ("NervGen" or the "Company"), a clinical stage biotech company dedicated to developing innovative solutions for the treatment of nervous system damage, announced that the Company has granted 400,000 incentive stock options to directors of...
Themefolio
Profiler
Peergroup
Advertisment
20.10.2025
© Newsfile
19.05.2023
NGEN
LISTED
TSX
NervGen Pharma Announces Results of Annual General Meeting of Shareholders
News Preview
All resolutions submitted for approval were passed by shareholdersVancouver, British Columbia--(Newsfile Corp. - May 18, 2023) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQX: NGENF), a clinical stage biotech company dedicated to developing innovative solutions for the treatment of nervous system damage, announces the results of its Annual General Meeti...
Themefolio
Profiler
Peergroup
© Newsfile
15.05.2023
NGEN
LISTED
TSX
NervGen Pharma Reports Q1 2023 Results and Provides Operational Update Including Clinical Trials of Proprietary NVG-291
News Preview
Phase 1 clinical trial dosing completedPhase 1b/2a clinical trial of NVG-291 in individuals with chronic and subacute spinal cord injuries expected to commence in Q3 2023Cash and investments of $18.0 million as of March 31, 2023Vancouver, British Columbia--(Newsfile Corp. - May 15, 2023) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQX: NGENF) ("NervGen"...
Themefolio
Profiler
Peergroup
© Newsfile
13.04.2023
NGEN
LISTED
TSX
NervGen Pharma Presenting Phase 1b/2a Study Design at American Spinal Injury Association 50th Annual Scientific Meeting
News Preview
Phase 1b/2a trial expected to commence in Q3 2023First readout anticipated in 2024Vancouver, British Columbia--(Newsfile Corp. - April 13, 2023) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQX: NGENF) ("NervGen" or the "Company"), a clinical stage biotech company dedicated to developing innovative solutions for the treatment of nervous system damage, wi...
Themefolio
Profiler
Peergroup
© Newsfile
10.04.2023
NGEN
LISTED
TSX
NervGen Pharma Appoints Michael Kelly as President & Chief Executive Officer
News Preview
Vancouver, British Columbia--(Newsfile Corp. - April 10, 2023) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQX: NGENF) ("NervGen" or the "Company"), a clinical stage biotech company dedicated to developing innovative solutions for the treatment of nervous system damage, today announced the appointment of Mr. Michael Kelly to the position of President &#...
Themefolio
Profiler
Peergroup
© Newsfile
30.03.2023
NGEN
LISTED
TSX
NervGen Pharma Reports 2022 Year End Results and Provides Operational Update Including Plans to Initiate Phase 1b/2a Clinical Trial of Proprietary NVG-291 in Q3 2023
News Preview
Equity proceeds of CA$22M+ raised during 2022 fiscal yearPhase 1 clinical trial dosing of proprietary compound, NVG-291, is complete and data analysis is ongoingPhase 1b/2a clinical trial of NVG-291 to include individuals with chronic and subacute spinal cord injuriesVancouver, British Columbia--(Newsfile Corp. - March 30, 2023) - NervGen Pharma Co...
Themefolio
Profiler
Peergroup
© Newsfile
24.02.2023
NGEN
LISTED
TSX
NervGen Pharma Grants Stock Options
News Preview
Vancouver, Canada--(Newsfile Corp. - February 23, 2023) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQX: NGENF) ("NervGen" or the "Company"), a clinical stage biotech company dedicated to developing innovative solutions for the treatment of nervous system damage, announced that the Company has granted 285,000 incentive stock options to directors of the...
Themefolio
Profiler
Peergroup
© Newsfile
14.02.2023
NGEN
LISTED
TSX
NervGen Pharma Announces Completion of Dosing of All Subjects in Phase 1 Clinical Trial of Proprietary Drug Candidate NVG-291
News Preview
Completed NVG-291 dosing of subjects in Phase 1 clinical trialPhase 1b/2a clinical trial of NVG-291 in individuals with spinal cord injury planned to start in Q3 2023NVG-291 has been demonstrated in preclinical studies to promote repair mechanisms in the nervous system, including axonal regeneration, remyelination and plasticity Vancouver, Britis...
Themefolio
Profiler
Peergroup
© Newsfile
17.11.2022
NGEN
LISTED
TSX
NervGen Pharma Announces Composition of Matter Patent for NVG-291 Granted by the US Patent and Trade Office
News Preview
Vancouver, British Columbia--(Newsfile Corp. - November 17, 2022) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQX: NGENF) ("NervGen" or the "Company"), a clinical stage biotech company dedicated to developing innovative solutions for the treatment of nervous system damage, announced that the US Patent and Trade Office (USPTO) has issued US Patent No. 11...
Themefolio
Profiler
Peergroup
© Newsfile
16.11.2022
NGEN
LISTED
TSX
NervGen Pharma Grants Stock Options
News Preview
Vancouver, British Columbia--(Newsfile Corp. - November 15, 2022) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQX: NGENF) ("NervGen" or the "Company"), a clinical stage biotech company dedicated to developing innovative solutions for the treatment of nervous system damage, announced that the Company has granted 400,000 incentive stock options to directo...
Themefolio
Profiler
Peergroup
© Newsfile
14.11.2022
NGEN
LISTED
TSX
NervGen Pharma Completes Dosing in Its Third Multiple Ascending Dose Cohort in Phase 1 Clinical Trial of NVG-291 and Reports Q3 2022 Results
News Preview
Dosing completed in third dose cohort of multiple ascending dose (MAD) portion of Phase 1 clinical trial in postmenopausal femalesU.S. Food and Drug Administration (FDA) amendment of partial clinical hold allows for bridging cohorts of males and premenopausal females in the Phase 1 trial to commenceGlenn Ives appointed as Lead Independent DirectorV...
Themefolio
Profiler
Peergroup
© Newsfile
31.10.2022
NGEN
LISTED
TSX
NervGen Engages Cloutier Consulting to Provide Media Relations Services
News Preview
Vancouver, British Columbia--(Newsfile Corp. - October 31, 2022) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQX: NGENF) ("NervGen" or the "Company"), a clinical stage biotech company dedicated to developing innovative solutions for the treatment of nervous system damage, announced that it has engaged Cloutier Consulting, a Texas based public relations...
Themefolio
Profiler
Peergroup
© Newsfile
25.10.2022
NGEN
LISTED
TSX
NervGen Pharma Receives FDA Authorization to Expand Enrollment of Males and Premenopausal Females in Phase 1 Clinical Trial of NervGen's NVG-291
News Preview
Dose(s) to be tested in bridging cohorts of males and premenopausal females resulted in significant functional improvements in animal models of nervous system damageNervGen has completed enrollment of third and final multiple ascending dose cohort of postmenopausal womenVancouver, British Columbia--(Newsfile Corp. - October 25, 2022) - NervGen Phar...
Themefolio
Profiler
Peergroup
© Newsfile
20.10.2022
NGEN
LISTED
TSX
NervGen Pharma Presenting at Upcoming Scientific Meetings
News Preview
AMERICAN NEUROLOGICAL ASSOCIATION ANNUAL MEETINGEUROPEAN COMMITTEE FOR TREATMENT AND RESEARCH IN MULTIPLE SCLEROSIS Vancouver, British Columbia--(Newsfile Corp. - October 20, 2022) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQX: NGENF) ("NervGen" or the "Company"), a clinical stage biotech company dedicated to developing innovative solutions for the tr...
Themefolio
Profiler
Peergroup
© Newsfile
12.10.2022
NGEN
LISTED
TSX
NervGen Pharma Awarded up to $1.5 Million US Department of Defense Funding to Evaluate NervGen's NVG-291-R for Peripheral Nerve Injury
News Preview
The $1.5 million award is to evaluate the ability of NervGen's NVG-291-R to accelerate and enhance restoration of function following peripheral nerve injury (PNI)The research is to support a potential game changing therapeutic approach to restore function for US military service members and the estimated 20+ million Americans suffering from PNI The...
Themefolio
Profiler
Peergroup
© Newsfile
29.09.2022
NGEN
LISTED
TSX
NervGen Pharma Announces Results of Annual General Meeting of Shareholders
News Preview
All resolutions submitted for approval were passed by shareholdersVancouver, British Columbia--(Newsfile Corp. - September 29, 2022) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQX: NGENF), a clinical stage biotech company dedicated to developing a first-in-class neuroreparative drug to treat nervous system damage, announces the results of its Annual Ge...
Themefolio
Profiler
Peergroup
© Newsfile
23.09.2022
NGEN
LISTED
TSX
NervGen Pharma Announces Leadership Transition
News Preview
Bill Radvak, Co-founder and Executive Chairman of the Board, appointed interim Chief Executive Officer Dr. Adam Rogers, member of the Board of Directors, appointed interim President Paul Brennan to step down as President & Chief Executive Officer and member of the Board of Directors; will serve as a strategic advisor for a transition periodVanc...
Themefolio
Profiler
Peergroup
© Newsfile
12.09.2022
NGEN
LISTED
TSX
NervGen Pharma Announces Appointment of Dr. Matvey Lukashev as Vice President, Research and Preclinical Development
News Preview
Expands research capabilities aiming to build pipeline of proprietary compounds for nervous system repairDr. Lukashev brings over 20 years' experience including work at Biogen and the ALS Therapy Development Institute Vancouver, British Columbia--(Newsfile Corp. - September 12, 2022) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQX: NGENF) ("NervGen" or...
Themefolio
Profiler
Peergroup
© Newsfile
08.09.2022
NGEN
LISTED
TSX
NervGen Pharma Presenting at Upcoming Military Health System Research Symposium and the 61st International Spinal Cord Society Annual Scientific Meeting
News Preview
Vancouver, British Columbia--(Newsfile Corp. - September 8, 2022) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQX: NGENF) ("NervGen" or the "Company"), a clinical stage biotech company dedicated to developing innovative solutions for the treatment of nervous system damage, will present a poster at the upcoming Military Health System Research Sympo...
Themefolio
Profiler
Peergroup
© Newsfile
10.08.2022
NGEN
LISTED
TSX
NervGen Pharma Reports Second Quarter 2022 Results and Provides Corporate Update
News Preview
Cash position enhanced by over $22 million due to private placement and exercise of warrants and optionsDosing in third dose cohort of multiple ascending dose (MAD) portion of Phase 1 clinical trial ongoingDiscussions ongoing with FDA regarding partial clinical holdUpdate provided on developments with US Government related to non-dilutive funding i...
Themefolio
Profiler
Peergroup
© Newsfile
02.08.2022
NGEN
LISTED
TSX
NervGen Presenting Study Design for Upcoming Phase 1b/2a in Alzheimer's Disease at the 2022 Alzheimer's Association International Conference
News Preview
Vancouver, British Columbia--(Newsfile Corp. - August 2, 2022) - NervGen Pharma Corp., (TSXV: NGEN) (OTCQX: NGENF), a clinical stage biotech company dedicated to developing a first-in-class neuroreparative drug to treat nervous system damage, will present the study design for its upcoming Phase 1b/2a Alzheimer's disease clinical trial at the 2022 A...
Themefolio
Profiler
Peergroup
© Newsfile
15.07.2022
NGEN
LISTED
TSX
NervGen Pharma Grants Stock Options
News Preview
Vancouver, British Columbia--(Newsfile Corp. - July 15, 2022) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQX: NGENF) ("NervGen" or the "Company"), a clinical stage biotech company dedicated to developing a first-in-class neuroreparative drug to treat nervous system damage, announced that the Company has granted 150,000 incentive stock options to a dire...
Themefolio
Profiler
Peergroup
© Newsfile
14.07.2022
NGEN
LISTED
TSX
NervGen Pharma Closes US$15MM Private Placement and Appoints Dr. Adam Rogers to Board of Directors
News Preview
Vancouver, British Columbia--(Newsfile Corp. - July 14, 2022) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQX: NGENF) ("NervGen" the "Company"), a clinical stage biotech company dedicated to developing a first-in-class neuroreparative drug to treat nervous system damage, announced that it has closed its previously announced non-brokered private placemen...
Themefolio
Profiler
Peergroup
© Newsfile
11.07.2022
NGEN
LISTED
TSX
NervGen Pharma Provides Update on Closing of Private Placement
News Preview
NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATESVancouver, British Columbia--(Newsfile Corp. - July 11, 2022) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQX: NGENF) ("NervGen" the "Company"), a clinical stage biotech company dedicated to developing a first-in-class neuroreparative drug to treat nervous system dam...
Themefolio
Profiler
Peergroup
© Newsfile
30.06.2022
NGEN
LISTED
TSX
NervGen Pharma Corp. Announces US$15MM Non-Brokered Private Placement
News Preview
NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATESVancouver, British Columbia--(Newsfile Corp. - June 30, 2022) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQX: NGENF) ("NervGen" the "Company"), a clinical stage biotech company dedicated to developing a first-in-class neuroreparative drug to treat nervous system dam...
Themefolio
Profiler
Peergroup
© Newsfile
31.05.2022
NGEN
LISTED
TSX
NervGen Pharma Grants Stock Options
News Preview
Vancouver, British Columbia--(Newsfile Corp. - May 31, 2022) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQX: NGENF) ("NervGen" or the "Company"), a clinical stage biotech company dedicated to developing a first-in-class neuroreparative drug to treat nervous system damage, announced that the Company has granted 180,000 incentive stock options to a direc...
Themefolio
Profiler
Peergroup
© Newsfile
16.05.2022
NGEN
LISTED
TSX
NervGen Hosting Panel Discussion with Leading Experts at the 2022 Annual Meeting of American Spinal Cord Injury Association (ASIA)
News Preview
Panel discussion will focus on the successful translation of NervGen's lead compound, NVG-291, from animals to humans Leading spinal cord injury experts on the panel include Drs. Jerry Silver, Monica Perez and James GuestNervGen will also present at the International Investment Forum Vancouver, British Columbia--(Newsfile Corp. - May 16, 2022) - Ne...
Themefolio
Profiler
Peergroup
© Newsfile
12.05.2022
NGEN
LISTED
TSX
NervGen Pharma Receives Approval to Proceed to the Final Dose Cohort in Phase 1 Clinical Trial of NVG-291 and Reports Q1 2022 Results
News Preview
Safety Review Committee approves proceeding to third and highest dose cohort in multiple ascending dose portion of clinical trial No serious or severe adverse events reported in second dose cohort with NVG-291Successful completion of the second cohort establishes a clear pathway to selecting a dose for upcoming Phase 1b/2 clinical trials Vancouver...
Themefolio
Profiler
Peergroup
© Newsfile
13.04.2022
NGEN
LISTED
TSX
NervGen Pharma Appoints Craig Thompson to the Board of Directors
News Preview
30 years of industry experience from CEO of Nasdaq-listed biotech to Vice President, Marketing at PfizerExperience on 16 development stage products, 15 commercial stage products and numerous pre-clinical assets, in both start-up and large pharmaceutical companiesVancouver, British Columbia--(Newsfile Corp. - April 13, 2022) - NervGen Pharma Corp. (...
Themefolio
Profiler
Peergroup
© Newsfile
06.04.2022
NGEN
LISTED
TSX
NervGen Pharma Grants Stock Options
News Preview
Vancouver, British Columbia--(Newsfile Corp. - April 6, 2022) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQX: NGENF) ("NervGen" or the "Company"), a clinical stage biotech company dedicated to developing a first-in-class neuroreparative drug to treat nervous system damage, announced that the Company has granted 376,000 incentive stock options to Employ...
Themefolio
Profiler
Peergroup
© Newsfile
31.03.2022
NGEN
LISTED
TSX
NervGen Presenting Interim Phase 1 Clinical Trial Data for NVG-291 at the 2022 American Academy of Neurology Annual Meeting
News Preview
Human subjects now being enrolled in the second cohort of multiple ascending dose portion of the studyNVG-291 dose administered in the first cohort is already above the highest corresponding dose found to be efficacious in animal models and is substantially higher than the lower effective doses where dramatic functional improvements were observedVa...
Themefolio
Profiler
Peergroup
© Newsfile
23.03.2022
NGEN
LISTED
TSX
NervGen Pharma to Present at 2022 Virtual Growth Conference Presented by Maxim Group
News Preview
Engages Apaton Finance to Provide Investor Relations Services in EuropeVancouver, British Columbia--(Newsfile Corp. - March 23, 2022) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQX: NGENF) ("NervGen" or the "Company"), a clinical stage biotech company dedicated to developing innovative solutions for the treatment of nervous system damage, will be prese...
Themefolio
Profiler
Peergroup
© Newsfile
15.03.2022
NGEN
LISTED
TSX
NervGen Pharma Receives Approval from Safety Review Committee to Proceed to Second Cohort in Multiple Ascending Dose Portion of Phase 1 Clinical Trial of NVG-291
News Preview
The dose of NVG-291 in the first cohort is already above the highest corresponding dose that resulted in dramatic functional improvements in animal modelsApproval moves NervGen one step closer to Phase 1b/2 efficacy studies in Alzheimer's disease, multiple sclerosis and spinal cord injury patients later in 2022NervGen's proprietary NVG-291, has bee...
Themefolio
Profiler
Peergroup
© Newsfile
28.02.2022
NGEN
LISTED
TSX
NervGen Pharma Reports 2021 Year End Results and Provides Update on Phase 1 Study
News Preview
Vancouver, British Columbia--(Newsfile Corp. - February 28, 2022) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQX: NGENF) ("NervGen" or the "Company"), a clinical stage biotech company dedicated to developing innovative solutions for the treatment of nervous system damage, today reported its financial and operational results for the year ended Dece...
Themefolio
Profiler
Peergroup
© Newsfile
04.01.2022
NGEN
LISTED
TSX
NervGen Pharma Applauds President Biden Signing Defense Bill
News Preview
Department of Defense now able to Move Forward on Brain Plasticity ResearchCincinnati, Ohio--(Newsfile Corp. - January 4, 2022) - NervGen Pharma Corp., (TSXV: NGEN) (OTCQX: NGENF) through its subsidiary, NervGen US Inc., ("NervGen" or the "Company"), a clinical stage biotech company dedicated to creating innovative treatments for nervous...
Themefolio
Profiler
Peergroup
© Newsfile
22.12.2021
NGEN
LISTED
TSX
NervGen Pharma Receives Ethics Board Approval for Multiple Ascending Dose Portion of NVG-291 Phase 1 Trial
News Preview
Phase 1 program supports plan to start clinical trials in H2 2022 for NervGen's NVG-291 in spinal cord injury, multiple sclerosis and Alzheimer's disease indications Screening of healthy volunteers has already started for the trial's multiple ascending dose (MAD) portionIn preclinical studies, NVG-291 has been shown to promote repair of nervous sys...
Themefolio
Profiler
Peergroup
© Newsfile
29.11.2021
NGEN
LISTED
TSX
NervGen Pharma Corp. Closes Non-Brokered Private Placement
News Preview
NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATESVancouver, British Columbia--(Newsfile Corp. - November 29, 2021) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQX: NGENF) ("NervGen" the "Company"), a clinical stage biotech company dedicated to creating innovative solutions for the treatment of nervous system damage...
Themefolio
Profiler
Peergroup
© Newsfile
18.11.2021
NGEN
LISTED
TSX
NervGen Pharma Reports Third Quarter 2021 Results
News Preview
Vancouver, British Columbia--(Newsfile Corp. - November 18, 2021) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQX: NGENF) ("NervGen" or the "Company"), a clinical stage biotech company dedicated to developing innovative solutions for the treatment of nervous system damage, today reported its financial and operational results for the third quarter ended...
Themefolio
Profiler
Peergroup
© Newsfile
12.11.2021
NGEN
LISTED
TSX
NervGen Pharma Completes $9.2 Million Bought Deal Financing
News Preview
NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATESVancouver, British Columbia--(Newsfile Corp. - November 12, 2021) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQX: NGENF) ("NervGen" or the "Company"), a clinical stage biotech company dedicated to creating innovative treatments for nervous system damage, is pleased...
Themefolio
Profiler
Peergroup
© Newsfile
05.11.2021
NGEN
LISTED
TSX
NervGen Pharma Announces Increase to Bought Deal Financing to $8.0 Million
News Preview
NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATESVancouver, British Columbia--(Newsfile Corp. - November 5, 2021) - NervGen Pharma Corp., (TSXV: NGEN) (OTCQX: NGENF) ("NervGen" or the "Company"), a clinical stage biotech company dedicated to creating innovative treatments for nervous system damage, is pleased...
Themefolio
Profiler
Peergroup
© Newsfile
04.11.2021
NGEN
LISTED
TSX
NervGen Pharma Announces $5,000,000 Bought Deal Financing
News Preview
NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATESVancouver, British Columbia--(Newsfile Corp. - November 4, 2021) - NervGen Pharma Corp., (TSXV: NGEN) (OTCQX: NGENF) ("NervGen" or the "Company"), a clinical stage biotech company dedicated to creating innovative treatments for nervous system damage, is pleased...
Themefolio
Profiler
Peergroup
© Newsfile
04.11.2021
NGEN
LISTED
TSX
NervGen Presents Additional Phase 1 Clinical Trial Data for NVG-291 at Neuroscience 2021
News Preview
Safety Review Committee Provides Recommendation to Proceed to Multiple Ascending Dose Portion of the TrialVancouver, British Columbia--(Newsfile Corp. - November 4, 2021) - NervGen Pharma Corp., (TSXV: NGEN) (OTCQX: NGENF) ("NervGen" or the "Company"), a clinical stage biotech company dedicated to creating innovative treatments for nervous system d...
Themefolio
Profiler
Peergroup
© Newsfile
27.10.2021
NGEN
LISTED
TSX
NervGen Pharma Announces Spinal Cord Injury Clinical Advisory Board
News Preview
Vancouver, British Columbia--(Newsfile Corp. - October 27, 2021) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQX: NGENF) ("NervGen" or the "Company"), a clinical stage biotech company dedicated to creating innovative treatments for nervous system damage, today announced the formation of its Spinal Cord Injury (SCI) Clinical Advisory Board comprised of f...
Themefolio
Profiler
Peergroup
© Newsfile
18.10.2021
NGEN
LISTED
TSX
NervGen Presents Interim Phase 1 Clinical Trial Data for NVG-291 at the American Neurological Association 14th Annual Meeting
News Preview
NVG-291 Demonstrated to be Well Tolerated Along with a Favorable Pharmacokinetic ProfileVancouver, British Columbia--(Newsfile Corp. - October 18, 2021) - NervGen Pharma Corp., (TSXV: NGEN) (OTCQX: NGENF) ("NervGen" or the "Company"), a clinical stage biotech company dedicated to creating innovative treatments for nervous system damage, provided a...
Themefolio
Profiler
Peergroup
© Newsfile
04.10.2021
NGEN
LISTED
TSX
U.S. Senate Defense Bill Includes NervGen Supported Language on Promise of Brain Plasticity Therapeutics for Traumatic Brain Injury
News Preview
Cincinnati, Ohio--(Newsfile Corp. - October 4, 2021) - NervGen Pharma Corp., through its subsidiary, NervGen US Inc., (TSXV: NGEN) (OTCQX: NGENF) ("NervGen" or the "Company"), a clinical stage biotech company dedicated to creating innovative treatments for nervous system damage, applauds the United States Senate Armed Services Committee for its rel...
Themefolio
Profiler
Peergroup
© Newsfile
27.09.2021
NGEN
LISTED
TSX
NervGen Pharma Partners with Imeka to Use Novel Neuroimaging Technology in Clinical Trials
News Preview
Vancouver, British Columbia--(Newsfile Corp. - September 27, 2021) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQX: NGENF) ("NervGen" or the "Company"), a clinical stage biotech company dedicated to developing innovative solutions for the treatment of nervous system damage today announced a partnership with Imeka Solutions Inc. ("Imeka"), currently the...
Themefolio
Profiler
Peergroup
© Newsfile
15.09.2021
NGEN
LISTED
TSX
NervGen Pharma Grants Stock Options
News Preview
Vancouver, British Columbia--(Newsfile Corp. - September 14, 2021) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQX: NGENF) ("NervGen" or the "Company"), a clinical stage biotech company dedicated to creating innovative solutions for the treatment of nervous system damage, today announced that the Company has granted 550,000 incentive stock options to Di...
Themefolio
Profiler
Peergroup
© Newsfile
13.09.2021
NGEN
LISTED
TSX
Encode Ideas, L.P. Announces the Initiation of Research Coverage on NervGen Pharma Corp.
News Preview
Dover, Delaware--(Newsfile Corp. - September 13, 2021) - Encode Ideas, L.P. Initiates Research on NervGen Pharma Corp. (TSXV: NGEN) (OTCQX: NGENF). The full research publication can be found on our website at www.encodelp.com, or by clicking here.Encode Ideas, L.P., a healthcare focused research firm, announced today it is initiating coverage on Ne...
Themefolio
Profiler
Peergroup
© Newsfile
12.09.2021
NGEN
LISTED
TSX
NervGen Pharma Presenting at the H.C. Wainwright 23rd Annual Global Investment Conference
News Preview
Vancouver, British Columbia--(Newsfile Corp. - September 12, 2021) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQX: NGENF) ("NervGen" or the "Company"), a clinical stage biotech company dedicated to developing innovative solutions for the treatment of nervous system damage, will be presenting at the H.C. Wainwright 23rd Annual Global Investment Conferen...
Themefolio
Profiler
Peergroup
Long/Short | Fractionals | Margin | Hedge · 4 powerful Trading App | MT4.MT5.ACTIVTRADER | TradingViewplus
More information, click here
More sector specific news
Your Press Release is missing or you want share news over GICS11? Drop us a line.
